News

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Founded in Keswick, Virginia, BIO-CAT is an industry-leading expert in specialty enzyme and probiotic formulations. The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health. BIO-CAT Microbials, located in Shakopee Minnesota, is BIO-CAT’s vertically integrated FDA registered and SQF certified (human-grade) U.S. fermentation facility. Their AAFCO-listed OPTIFEED® probiotic strains are premium, safe, effective, and have shown physiological benefits to companion animals in support of their gastrointestinal and digestive health; similar to the benefits they deliver to humans. Future expansion of the OPTIFEED® line of enzymes will further support digestive health, enhancing the nutritional value of pet food, and can be used in ingredient processing and flavor development.

“This partnership with BIO-CAT significantly strengthens Caldic’s existing Companion Animal portfolio,” says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, “adding a range of innovative and customizable solutions to inspire quality pet food and health. As the importance of pet companionship is widely recognized, domestic animal owners are increasingly keen to provide their pets with nutritionally high-performing food, treats and supplements. The expert know-how our R&D team has acquired in pet food when formulating with our antioxidants range, Dadex®, and our custom vitamin and mineral blends, Daminaide®, will greatly benefit the solutions we can deliver across North America while partnering with BIO-CAT.”

“BIO-CAT Microbials’ expertise in probiotic strain development and fermentation is a great match for Caldic’s exceptional distribution solutions,” says Chris Schuler, President and CEO of BIO-CAT. “We value Caldic’s commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base. We look forward to a successful collaboration and exclusive partnership with Caldic.”

Recent News

04/29/2025

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital construction project in the 95-year-old university’s history — a new biological sciences building. The planned five-story, 162,586 square-foot building will be located on ODU‘s campus in Norfolk, near the university’s Oceanography and Mills Godwin Life Sciences buildings. ODU spokesperson Jonah Ross Grinkewitz said the

04/29/2025

Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead New Division of Pediatrics and Special Populations

Dr. Eskandanian, a global leader in pediatric innovation, joins Compremium from Children’s National Hospital in Washington, D.C., where she most recently served as Vice President and Chief Innovation Officer, Executive Director of the Sheikh Zayed Institute for Pediatric Surgical Innovation, and founding executive of Innovation Ventures. Her appointment marks a strategic milestone in Compremium’s expansion

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the